What is the Biotech Investor Readiness Scorecard?

The Bridge BioHealth Investor Readiness Scorecard is an MBA-level 5-dimension assessment that evaluates your biotech startup across pitch quality, science validation, team strength, market position, and financial health — the same dimensions institutional biotech VCs apply. It generates a scored report with specific, actionable improvements.

How is the investor readiness score calculated?

The score is calculated across 5 weighted dimensions: Pitch & Narrative (20%), Science & Pipeline (25%), Team & Governance (20%), Market & Competitive (20%), and Financials & Runway (15%). Each dimension is scored based on your responses and weighted to reflect how institutional biotech VCs prioritize these factors.

Is the Investor Readiness Scorecard free?

The basic scorecard is free to complete. A premium PDF report with AI-generated investor narrative, pitch deck recommendations, funding strategy, and VC outreach playbook is available for $149.

Bridge BioHealthConsulting LLC

Book Consultation

Investor Readiness Intelligence

Before You Pitch,
Score Yourself First.

90% of biotech fundraising failures are preventable. Our 5-dimension Investor Readiness Scorecard gives you the honest, evidence-based assessment VCs will apply — before you burn a single relationship.

Start Readiness Assessment Resolve with BB Solver

Pitch & Narrative

Science Validation

Team & Governance

Market Position

Financial Health

The Stakes

Most Biotech Fundraising Fails Before the First Meeting.

85%

of biotech decks never make it past the first-pass VC screen

PitchBook Biotech Report, 2024

300+

decks reviewed per year by a single biotech VC associate

Industry survey, 2023

<2%

cold outreach response rate in the current biotech funding climate

Bridge BioHealth Network Data, 2024

Pitch Quality Audit

We evaluate your narrative clarity, differentiation, traction evidence, and milestone mapping — the four things VCs filter on in the first 60 seconds.

Science Diligence Preview

We assess your mechanism validation, IP position, data quality, and regulatory pathway — the questions that dominate scientific due diligence.

Team Credibility Score

We evaluate founder experience, SAB strength, management depth, and key-person risk — the #1 criterion for biotech investors.

Market & Exit Viability

We assess TAM, competitive moat, partnership interest, and exit clarity — the commercial logic that justifies the valuation.

Financial Reality Check

We evaluate burn rate, runway, valuation expectations, and use-of-funds clarity — the operational basics that kill more deals than bad science.

Actionable Improvement Plan

Every report includes a prioritized list of specific, actionable improvements — not generic advice, but targeted fixes for your exact profile.

Investor Readiness Assessment

5-Dimension Fundraising Scorecard

6 steps. ~8 minutes. MBA-level investor intelligence grounded in biotech VC research and Bridge BioHealth fundraising analytics.

1Company Profile

2Pitch & Narrative

3Science & Pipeline

4Team & Governance

5Market & Competitive

6Financials & Runway

Step 1: Company Profile

Step 1 of 6

Confidentiality: Use a code name only. Do not enter real company names, ticker symbols, or identifying information.

Company Code Name *

Company Stage

Primary Modality

Therapeutic Area

Lead Asset Stage

Pipeline Depth

Legal Disclaimer: The Bridge BioHealth Investor Readiness Scorecard is provided for strategic decision-support purposes only and does not constitute investment, financial, or legal advice. Bridge BioHealth Consulting LLC is not a registered investment advisor. All fundraising decisions should be independently verified by qualified financial and legal advisors. © 2026 Bridge BioHealth Consulting LLC.

We use cookies to improve your experience.

We use essential and analytics cookies to operate our platform and understand how visitors use it. See our Privacy Policy for details.

Before You Pitch,Score Yourself First.